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ABSTRACT Mycobacterium tuberculosis remains a major cause of death due to the lack of treatment accessibility, HIV coinfec-
tion,anddrugresistance.Developmentofnewdrugstargetingpreviouslyunexploredpathwaysisessentialtoshortentreatment
time and eliminate persistent M. tuberculosis. A promising biochemical pathway which may be targeted to kill both replicating
and nonreplicating M. tuberculosis is the biosynthesis of NAD(H), an essential cofactor in multiple reactions crucial for respira-
tion,redoxbalance,andbiosynthesisofmajorbuildingblocks.NaMNadenylyltransferase(NadD)andNADsynthetase(NadE),
the key enzymes of NAD biosynthesis, were selected as promising candidate drug targets for M. tuberculosis. Here we report for
theﬁrsttimekineticcharacterizationoftherecombinantpuriﬁedNadDenzyme,settingthestageforitsstructuralanalysisand
inhibitordevelopment.AproteinknockdownapproachwasappliedtovalidatebothNadDandNadEastargetenzymes.Induced
degradationofeithertargetenzymeshowedastrongbactericidaleffectwhichcoincidedwithanticipatedchangesinrelativelev-
elsofNaMNandNaADintermediates(substratesofNadDandNadE,respectively)andultimatedepletionoftheNAD(H)pool.
AmetaboliccatastrophepredictedasalikelyresultofNAD(H)deprivationofcellularmetabolismwasconﬁrmedby 13Cbiosyn-
theticlabelingfollowedbygaschromatography-massspectrometry(GC-MS)analysis.Asharpsuppressionofmetabolicﬂuxwas
observedinmultipleNAD(P)(H)-dependentpathways,includingsynthesisofmanyaminoacids(serine,proline,aromatic
aminoacids)andfattyacids.Overall,theseresultsprovidestrongvalidationoftheessentialNADbiosyntheticenzymes,NadD
andNadE,asantimycobacterialdrugtargets.
IMPORTANCE To address the problems of M. tuberculosis drug resistance and persistence of tuberculosis, new classes of drug tar-
getsneedtobeexplored.ThebiogenesisofNADcofactorswasselectedfortargetvalidationbecauseoftheirindispensablerolein
drivinghundredsofbiochemicaltransformations.WehypothesizedthatthedisruptionofNADproductioninthecellviage-
neticsuppressionoftheessentialenzymes(NadDandNadE)involvedinthelasttwostepsofNADbiogenesiswouldleadtocell
death,evenunderdormancyconditions.Inthisstudy,weconﬁrmedthehypothesisusingaproteinknockdownapproachinthe
model system of Mycobacterium smegmatis. We showed that induced proteolytic degradation of either target enzyme leads to
depletionoftheNADcofactorpool,whichsuppressesmetabolicﬂuxthroughnumerousNAD(P)-dependentpathwaysofcentral
metabolismofcarbonandenergyproduction.Remarkably,bactericidaleffectwasobservedevenfornondividingbacteriaculti-
vatedundercarbonstarvationconditions.
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W
ith the continuing problem of tuberculosis (TB) com-
pounded by the HIV epidemic and the emergence of in-
creasingratesofdrugresistance,thereremainsaneedfornewand
more effective antibiotics aimed at previously unexplored targets.
Among potential targets identiﬁed by a variety of genomic tech-
niques, there are many indispensable metabolic enzymes (1, 2).
Whilecentralmetabolicprocesseswerefoundtoberecalcitrantto
antibiotic development, certain enzymes responsible for the syn-
thesisoftheessentialcofactorfolate(FolAandFolP)wereproven
to be reliable targets for antibacterial drugs (trimethoprim and
sulfonamides).Biosynthesisofthenicotinamideadeninedinucle-
otide(NAD)cofactorappearstobeanotherprominentcandidate
target pathway in many bacterial pathogens (3–8), including My-
cobacterium tuberculosis (9, 10). Indeed, NAD(H) and its phos-
phorylated derivative NADP(H) are irreplaceable cofactors in
~17% of 849 enzymatic reactions included in an M. tuberculosis
metabolicmodel(11).Amongthesearethekeypathwaysrequired
to produce ATP, pathways already validated by the newly ap-
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likely plays a key role in survival in limited oxygen environments
in M. tuberculosis, which utilizes the anaerobic electron transport
chain to maintain a necessary redox balance within a pool of
NAD-related cofactors to persist in a nonreplicating state (14). In
additiontoitsroleasanessentialredoxcofactorinoverahundred
central metabolic reactions, NAD is subject to rapid degradation
inthecell(withaturnoverhalf-life[t1/2]of~90mininEscherichia
coli[15])byavarietyofnonmetabolicenzymesutilizingNADasa
substrateinDNArepair,proteindeacetylation,ADPribosylation,
etc. Therefore, biosynthetic NAD replenishment is required to
maintainthepoolofNADcofactors,astheycannotbetakenupby
microbial cells (except for some obligate intracellular pathogens
such as Chlamydia [16]).
Genomics-based reconstruction (7, 10) (Fig. 1) and experi-
mental data (9) suggest that the two upstream routes of NAD
biogenesis, de novo synthesis (enzymes NadA, NadB, and NadC)
and vitamin B3 salvage (PncA and PncB), are functionally redun-
dant and are, therefore, poor candidates for the development of
inhibitors. On the other hand, the last two consecutive steps of
NAD biosynthesis from a nicotinate mononucleotide (NaMN)
precursor via a nicotinate adenine dinucleotide (NaAD) interme-
diate (see Fig. 1) appear to be irreplaceable. The respective en-
zymes, NaMN adenylyltransferase (NadD) and NAD synthetase
(NadE), are conserved in most bacterial species, being quite dis-
tinctfromtheirhumancounterparts(7).Thesebacterialenzymes
havebeenextensivelycharacterized(17,18)andtargetedfordrug
development in both Gram-positive and Gram-negative bacteria
(6, 19–22). Both nadD and nadE genes are conserved in all se-
quenced mycobacterial genomes (see Table S1 in the supplemen-
FIG 1 Targeting indispensable enzymes of NAD biosynthesis is expected to cause global metabolic catastrophe. In the simpliﬁed diagram of genomics-based
reconstruction of NAD biogenesis and homeostasis (upper panel; for details, see Table S1 in the supplemental material), the key intermediary metabolites are
shown by abbreviations in circles as follows: Asp, aspartate; Na, nicotinic acid; Nm, nicotinamide; NmR, nicotinamide riboside; NaMN, nicotinic acid mono-
nucleotide; NMN, nicotinamide mononucleotide; NaAD, nicotinic acid adenine dinucleotide. Enzymes are indicated as products of the respective genes above
correspondingbiochemicaltransformations(arrows).Essentialenzymaticstepsareoutlinedinred,andtwoenzymesselectedastargetsinthisstudy,nicotinate
mononucleotide adenylyltransferase (NadD) and NAD synthetase (NadE), are marked by an asterisk (*). Our study results suggest that the NadR-dependent
pathwayofNmRsalvageisnonfunctionalinM.tuberculosis(shownbygreyandindicatedbyquestionmarks),whichhasnotypicalPnuC-likeNmRtransporter.
The NadR homolog, which is present in M. tuberculosis but not in M. smegmatis, appears to lack both of the enzymatic activities, corresponding to NmR kinase
and NMN adenylyltransferase, reported for the bifunctional NadR enzyme from some gammaproteobacteria. As NAD constantly undergoes nonredox degra-
dation (only some of NAD-degrading enzymes are shown), blocking its de novo synthesis, salvage, and recycling pathways via inactivation of a downstream
enzyme(s), NadD or NadE, would impair the homeostasis of all four functional forms of NAD-related cofactors (middle panel). A resulting cofactor shortfall
would suppress metabolic ﬂux in hundreds of redox reactions comprising all essential pathways of central carbon and energy metabolism (lower panel).
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studies in M. tuberculosis (23–25).
Therefore, one of the main goals of this study was to assess the
potential utility of both enzymes, NadD and NadE, as antimyco-
bacterial drug targets. NadE from M. tuberculosis has been previ-
ously characterized in detail, including structural analysis (26–
28); some NadE inhibitors inhibited M. tuberculosis growth in
vitro(9).Here,fortheﬁrsttime,wereportcloning,expressionand
enzymatic characterization of NadD from M. tuberculosis.W e
used a recently described targeted protein degradation approach
(29) to test the essentiality of NadD and NadE and determine the
biochemical and biological consequences of depletion of these
target enzymes. We found that both are required for not only the
growth but also the survival of the model organism Mycobacte-
rium smegmatis. We also found that a homolog of NadR protein
from M. tuberculosis is not able to complement NadD or NadE
depletion in M. smegmatis, supporting the idea of the universal
essentialityofthesetargetenzymes.Usingmassspectrometryand
stable isotope tracers, we conﬁrmed expected perturbations in
NAD biosynthetic pathways resulting from inactivation of NadD
and NadE enzymes and global changes in central carbon metabo-
lism triggered by the induced depletion of the NAD(H) cofactor
pool. The observed network-scale impact, which could not be as-
sessed by traditional genetic techniques, provided an additional
strong rationale for pursuing these enzymes as antimycobacterial
drug targets.
RESULTS
NadDandNadEareindispensableenzymesofNADbiosynthe-
sis conserved in all mycobacterial genomes. Comparative
genomics-basedreconstructionofNADmetabolism(capturedby
us in the relevant SEED subsystem [30]) showed that most fea-
tures characteristic of M. tuberculosis (10) are conserved in all
other sequenced genomes of mycobacterial species. Brieﬂy, they
includethefollowing(Fig.1):(i)denovosynthesisofNaMNfrom
aspartate(nadABCgenes);(ii)aredundantsalvage/recycling(pn-
cAB) route of NaMN synthesis from nicotinamide (Nm) or nico-
tinic acid (Na); and (iii) downstream conversion of NaMN to
NAD via an NaAD intermediate by two consecutive reactions
(genesnadDandnadE).Basedonthisnetworktopology,thelatter
two enzymes appear to be indispensable in all mycobacteria, in
agreement with some experimental ﬁndings in M. tuberculosis (9,
23).Incontrast,aNadRhomolog(NadRh)ispresentinonlysome
species of mycobacteria, e.g., in M. tuberculosis, Mycobacterium
bovis, and Mycobacterium microti but not in M. smegmatis and
many others (see Table S1 in the supplemental material). Al-
though the prototype NadR protein is known to drive two-step
NAD synthesis in Haemophilus inﬂuenzae following the uptake of
exogenous nicotinamide riboside (NmR) via a committed trans-
porter, PnuC (8, 31), the actual function of NadRh in M. tubercu-
losis (28% identity with hi_NadR) is unclear. No homologs of
PnuC are present in NadRh-containing species of mycobacteria,
suggesting that NadRh may be involved in NAD recycling rather
than biosynthesis or may play another, yet unknown, functional
role. Indeed, a recombinant puriﬁed NadRh from M. tuberculosis
did not show any detectable NmR kinase or NMN adenylyltrans-
ferase activity, whereas both activities of recombinant NadR pro-
teins from Salmonella enterica or H. inﬂuenzae could be readily
measured by the same assays (see Fig. S1 in the supplemental
material).
NadDfromM.tuberculosisisanNaMN-preferringadenylyl-
transferase. While previous attempts to express NadD from M.
tuberculosis failed to yield functionally active enzyme, here we re-
solvedthisproblembycorrectingthepositionofthetranslational
start of the nadD gene (see Fig. S2 in the supplemental material).
Indeed, expression in E. coli of the full-size protein with the N
terminus extended by 8 amino acids yielded functionally active
NaMN adenylyltransferase. In contrast, no activity was observed
when a shorter form of M. tuberculosis NadD (within the original
boundariesofGenBankGI:15609558)wasexpressedandpuriﬁed
using the same expression vector. The puriﬁed recombinant full-
size enzyme displayed the same speciﬁc activity before and after
proteolytic removal of the N-terminal SUMO-(His)6 tag. The
steady-state kinetics analysis conﬁrmed a strong substrate prefer-
ence for NaMN (with apparent values of Km  0.34  0.03 mM
andkcat4.50.1s1)overNMN(Km4.01.1mMandkcat
 0.043  0.005 s1) at saturating ATP, which translates to a
nearly 1,000-fold preference at the level of kcat/Km (see Fig. S2 in
the supplemental material). Such a stringent substrate preference
is characteristic of the members of bacterial NadD family, distin-
guishing them from the human counterpart enzyme (NMNAT),
which shows nearly equal levels of activity with both substrates
(32).
NadDorNadEknockdownhasstrongbactericidaleffectsin
an M. smegmatis model. A protein depletion method recently
developedandvalidatedinmycobacteria(29)allowedustoassess
bactericidaleffectsandexplorethemetabolicconsequencesofde-
pleting NadD and NadE enzymes in an M. smegmatis model sys-
tem. The induction of targeted proteolysis in each of the two en-
gineered strains (Fig. 2A) led to 90% degradation of NadD or
NadE enzymes within the ﬁrst2hb yboth Western blot and en-
zymaticactivityanalyses(Fig.2BandC).Theseeffectsweretarget
speciﬁc; depletion of one target enzyme had no effect on the ac-
tivity of another enzyme. Inactivation of either enzyme led to a
complete growth arrest by 6 h after induction (Fig. 2D). More-
over,theknockdown(KD)ofeitherNadDorNadEhadanappar-
ent bactericidal effect, as evidenced by a 1,000-fold decrease in
the number of viable cells (in CFU/ml) compared to the unin-
duced control whereas the drop in the overall cell number was
only 10-fold (Fig. 2E). A comparable bactericidal effect was ob-
served upon induction of NadD or NadE degradation after incu-
bation for 3 days under carbon starvation conditions (dormancy)
(see Fig. S4 in the supplemental material). Taken together, these
results provide the ﬁrst direct validation of both the NadD and
NadE enzymes as potential targets for the development of bacte-
ricidal agents against mycobacteria. The relevance of this conclu-
sion for M. tuberculosis is supported by the observation that the
expressionofthenadRhgenefromM.tuberculosisinM.smegmatis
didnotsuppressthebactericidaleffectoftheinduceddegradation
of NadD or NadE enzymes even when NmR was added to the
growth media (see Text S1 in the supplemental material).
NadDorNadEeliminationblocksNADsynthesis,leadingto
depletion of the cofactor pool. Liquid chromatography-mass
spectrometry (LC-MS)-based determination of NAD and its key
metabolicintermediatesincellextractsallowedustodirectlycon-
ﬁrm and assess the dynamics of blocking NAD biosynthesis upon
induced degradation of either target enzyme (Fig. 3; see also Ta-
ble S2 in the supplemental material). NadD knockdown led to
nearlycompletedepletionoftheNaADproductwithintheﬁrst2h
and a somewhat slower (at 4 to 6 h after induction) accumulation
Genetic Validation of NadD and NadE Drug Targets
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cofactor gradually decreased up to ~9-fold compared to unin-
duced control samples (normalized per total protein) within 8 h.
The depletion of the NAD pool was accompanied by a compa-
rabledepletionofthereduced(NADH)cofactorpool,asindepen-
dently assessed by a colorimetric assay (Fig. 3). Importantly,
NADH could not be replenished from NAD even though the
latter remained in excess. After depletion of NadE, the accumula-
tion of both precursors, NaMN and NaAD, was observed (Fig. 3),
with the most remarkable (100-fold) increase of the latter pool,
uptothelevelofNADinuninducedcontrol.Theoveralldynam-
icsandextentofdepletionofNAD(H)poolsweresimilartothose
observed in the case of NadD knockdown.
Notably, in both cases, a substantial accumulation of 13C-
labeled nicotinic acid (Na) in the medium was observed using a
gaschromatography-MS(GC-MS)approachat6hafterdepletion
FIG2 InduceddegradationofNadDandNadEhasastrongbactericidaleffectintheM.smegmatismodelsystem.(A)Identiﬁcationnumber(ID)-taggedNadD
and NadE are stable in the absence of HIV-2 protease, which is expressed only upon induction with anhydrotetracyclin. (B and C) When induction occurs,
proteolyticremovaloftheHIV-2proteaserecognitionsiteexposestheSsrArecognitionsiteandClp-mediatedproteolysisofNadDorNadEensues.Inducedand
uninducedcellsareindicatedasATc()andATc(),respectively.InductionbyATcleadstorapid(within2h)depletionoftargetenzymesasshownbyWestern
blot analysis with anti-Myc-tag antibodies (B) and measurement of respective enzymatic activities in crude extracts (C). Activity was measured by HPLC-based
assays;dataarepresentedinunits/mgoftotalprotein.(D)Depletionofeitherenzymeleadstogrowtharrest,monitoredbyOD600,within10h.(E)Inbothcases,
the bactericidal effect is observed as conﬁrmed by CFU analysis. Growth curves for NadD or NadE ATc () are shown with the symbol “”; growth curves for
ATc () are shown with the symbol “y.”
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notcompensatedforbyrecycling(whichrequiresbothNadDand
NadE activities), thus leading to product inhibition of PncB by a
buildup of NaMN.
NADcofactorpooldepletionleadstosuppressionofnumer-
ous central metabolic pathways. To explore mechanisms under-
lying bactericidal effects of NAD depletion, we assessed induced
changes in major central metabolic pathways using biosynthetic
13C labeling followed by GC-MS proﬁling of extracted metabo-
lites. The percentage of synthesis from glucose of metabolites was
calculated as the ratio of metabolite 13C labeling to 13C-glucose
labeling (33). We hypothesized that the strongest effects on syn-
thesis would be observed for the endpoint metabolites whose de
novo syntheses include indispensable NAD(P)-dependent steps.
We focused primarily on the time points at ~6 h postinduction
corresponding to a substantial depletion of the NAD pool but
before there was an appreciable difference in the CFU titers of
inducedanduninducedcultures.Nodifferenceintheuptakerates
ofthemaincarbonsources,glutamateand[U-13C6]glucose,from
the medium were observed within the time frame of the experi-
ment,supportingtheideaoftherelevanceofthiscomparison.We
obtained similar results with NadD (Fig. 4) and NadE (see Ta-
ble S3 in the supplemental material) knockdown.
NAD cofactor pool depletion strongly affected the synthesis of
various amino acids (Fig. 4). Synthesis of phenylalanine and ty-
rosine (speciﬁcally, fragments of these amino acids containing 
and  carbons) decreased with NAD depletion, while synthesis of
the common precursor, phosphoenolpyruvate (PEP), was unaf-
FIG 3 NadD and NadE inactivation yields accumulation of NAD metabolic precursors and depletion of the NAD(H) pool. LC-MS analysis of crude extracts
showedrapidaccumulationofNaMNanddepletionofNaAD(theNadDsubstrateandproduct,respectively)uponinductionofNadDdegradationfollowedby
the depletion of NAD pool. The same approach showed accumulation of both precursors, NaMN and NaAD (the NadE substrate), and depletion of NAD (the
NadE substrate) upon NadE knockdown. A colorimetric coupled assay conﬁrmed proportional depletions of the NADH pool in both NadD and NadE
knockdown experiments (bottom panels).
Genetic Validation of NadD and NadE Drug Targets
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common NAD-dependent enzyme, shikimate dehydrogenase;
therefore, suppression of its activity by the depletion of the NAD
cofactor pool could be responsible for the observed changes. Im-
portantly, the shikimate pathway plays a central role in the bio-
synthesis of other essential aromatic compounds along with
amino acids (e.g., quinones). It includes a number of experimen-
tally demonstrated essential genes that are considered potential
drug targets (34, 35). Another strong inhibitory effect could be
deducedfromserinesynthesis,whichwasdecreased~2-foldupon
NAD depletion, whereas there was no change in synthesis of its
upstream glycolytic intermediate, 3-phosphoglycerate (3-PG;
FIG4 DepletionoftheNADcofactorleadstosuppressionofmetabolicﬂuxovernumerousessentialNAD-dependentpathways.Astrongerearlyresponsewas
observed in pathways where multiple consecutive steps required NAD(P) cofactors as illustrated by several examples from [13C]glucose (13C-Glc) labeling and
GC-MS metabolite proﬁling studies (for additional data, see Table S3 in the supplemental material). In a simpliﬁed diagram of central metabolism, metabolites
are shown by abbreviations in circles as follows: 3PG, 3-phosphoglycerate; Asp, aspartate; Thr, threonine; Ile, isoleucine; PEP, phosphoenolpyruvate; Tyr,
tyrosine;Phe,phenylalanine;Ser,serine;Gly,glycine;Ac-CoA,acetyl-coenzymeA(acetyl-CoA);KG,-ketoglutarate;Cit,citrate;Suc,succinate;Fum,fumarate;
Mal, malate; OAA, oxaloacetate; Glu, glutamate; Glc, glucose; C16, C16:0 fatty acid; C24, C24:0 fatty acid. Redox reactions utilizing NAD(H) or NADP(H)
cofactors are marked by a red arrow. Dashed lines reﬂect multiple reactions. In graphs A to E, the percentages of de novo synthesis from glucose versus other
biosynthetic, salvage, or recycling ﬂuxes are compared for samples without (white bars) and with (gray bars) knockdown of NadD. Analyzed samples were
typically obtained at 6 h postinduction by ATc (except for C16 and C24, where measurements at 6 and 8 h are indicated) when the growth rates of induced and
noninducedcellsremainedcomparable(asdescribedforthelowerpanelinFig.1).InductionofNadEtypicallyshowedsimilareffects.(A)Chorismatepathway.
(B) Serine and glycine synthesis. (C) Amino acids derived from aspartate. (D) Fatty acid synthesis. (E) tricarboxylic acid (TCA) cycle.
Rodionova et al.
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sion of 3-phosphoglycerate dehydrogenase, the ﬁrst committed
step of the pathway. In addition to producing the amino acids
serine and glycine, this pathway contributes to essential folate-
mediated C1 metabolism. Biosynthesis of several aspartate-
derived amino acids was also responsive to NAD depletion. Thus,
synthesis of threonine and, to a greater extent, isoleucine de-
creased upon NadD knockdown (Fig. 4C). On the other hand,
synthesis of their precursor, aspartate, was unaffected (Fig. 4C).
This likely reﬂects the impact on the NAD-dependent enzyme
homoserinedehydrogenaseinthesynthesisofthreonine,whichis
further converted to isoleucine via a pathway containing an addi-
tional NADP-dependent enzyme, ketoacid reductoisomerase.
The involvement of downstream NAD-dependent enzymes did
not always translate to notably decreased synthesis of pathway
endpoints. Thus, lysine synthesis, which also includes one com-
mitted downstream NAD-dependent enzyme, dihydropicolinate
reductase, in addition to aspartate semialdehyde dehydrogenase
(shared with the Thr/Ile pathway), did not reveal any difference
between depleted and control cells (see Table S3 in the supple-
mental material). The absence of detectable differences may be
due to a variety of factors such as a relatively low dilution of 13C
label from unlabeled exogenous or endogenous metabolites.
Lack of NAD biosynthesis has an even more striking effect on
biosynthesisoffattyacids,asNADisrequiredforeveryelongation
cycle in fatty acid propagation. De novo synthesis of C16:0 and
C24:0 fatty acids was substantially (30% and 70%) diminished
upondepletionofNadD(Fig.4D).Theeffectwasstrongerforthe
longer-chain fatty acid, in keeping with a higher demand for
NAD-derived cofactors in its synthesis.
Finally, 13C labeling data also pointed to inhibitory effects of
NAD depletion on the functioning of the tricarboxylic acid cycle.
Indeed, while -ketoglutarate and succinate were derived equally
from glucose in NadD knockdown and control cells (Fig. 4E), the
synthesis from glucose of fumarate and malate was decreased in
knockdown cells, suggesting reduced activity of upstream NAD-
dependent enzymes (e.g., -ketoglutarate dehydrogenase) allow-
ing dilution of a depleted fumarate/malate pool by non-13C
sources, e.g., aspartate.
DISCUSSION
One of the earliest antibiotics used to treat TB, isoniazid, was
derived from the antituberculosis compound nicotinamide,
whichisalsoaprecursorinasalvagerouteofNADbiogenesisand
an inhibitor of NAD de novo synthesis in eukaryotic cells. While
isoniazidclearlyhasadifferentmodeofaction,NADhomeostasis
isimportantformycobacterialinfection,asdemonstratedinmice
forM.bovis(36).NADbiosynthesisrepresentsanattractivetarget
pathway for antibiotic development because of the central role of
NAD(P) cofactors that are driving at least 10% to 15% of the
chemical reactions in bacterial metabolic networks (2, 7, 10).
GenesencodingNadDandNadEenzymes,conservedamongbac-
terial species and proven to be essential in M. tuberculosis, are
attractiveandactivelypursueddrugtargets(6,9,19,21).Herewe
foundthattheinabilitytosynthesizeNADresultingfromtargeted
degradation of NadD or NadE enzymes led to rapid cell death in
M. smegmatis (Fig. 2). Given the pleiotropic effects on metabo-
lism, this is likely to be true in other mycobacteria, including M.
tuberculosis.Moreover,thispathwayhasothercharacteristicsthat
make it an attractive target for antibiotic development. There is
only limited similarity between mycobacterial NadD and the
functionally equivalent human NMNAT (7). Therefore, it should
be possible to produce speciﬁc inhibitors, as has been done for
otherbacterialNadDenzymes(6).Inaddition,theproteinknock-
downsystemweemployeddoesnotcompletelyeliminatetargeted
proteins (29). Thus, pharmacological agents that produce only
partial inhibition could be sufﬁcient to kill mycobacteria.
A metabolic proﬁling approach used in this study provided us
with the experimental evidence of NAD and NADH depletion
(Fig. 3) triggering global suppression of many central metabolic
pathways (Fig. 4). The observed effects were prominent in path-
ways heavily relying on redox reactions driven by NAD(P) cofac-
tors.Amongthemareknownessentialpathwaysoffattyacidsyn-
thesis (37), cholesterol catabolism (38), and synthesis of aromatic
compounds (35). An observed disruption of the Krebs cycle
would affect production of energy from respiration, which is im-
portantfortargetingthedormantformofM.tuberculosis.During
amonitoredearlyphaseofinterferencewithNADsynthesis(prior
to appreciable growth arrest), the ATP level slightly increased
rather than decreased. This transient accumulation likely reﬂects
sharply reduced consumption of ATP upon NAD(P) synthesis.
Indeed, the synthesis of 1 molecule of NADP from NaMN con-
sumes 3 molecules of ATP. A similar accumulation was observed
for aspartate, the starting-point metabolite of NAD de novo syn-
thesis.
NadD and NadE are essential in M. tuberculosis despite the
presence of a distant homolog of NadR protein (termed NadRh),
which is absent from M. smegmatis and many other species of
mycobacteria. In our hands, NadRh did not appear to contribute
to NAD biogenesis in M. tuberculosis, pointing to the overall re-
semblance of NAD metabolism in M. smegmatis to that in the
slowly growing mycobacterial pathogens. Altogether, our results
suggest that targeting NAD biosynthesis could lead to production
of highly effective bactericidal antituberculosis compounds. The
mechanismofactionofinhibitorsthatcouldbedevelopedagainst
presently characterized NadD or NadE enzymes is expected to
include the depletion of the NAD cofactor pool, resulting in the
collapse of the entire central metabolic network. Our results sug-
gest that many central metabolites could be used as reporters of
NADbiosynthesis,providingastartingpointforscreensforcom-
pounds directed toward this pathway.
MATERIALS AND METHODS
Reagents and bacterial strains. Recombinant puriﬁed enzymes for cou-
pled assays, NAD synthetase (NadE) from Bacillus anthracis and NMN
adenylyltransferase (NadM) from Acinetobacter baylyi, were from previ-
ous studies (3, 5). Other reagents can be found in Text S1 in the supple-
mentalmaterial.BacterialstrainsderivedfromM.smegmatisandM.bovis,
plasmids, and primers used in this study are listed in Table S4 in the
supplemental material.
CloningofM.tuberculosisnadgenes,heterologousexpression,and
puriﬁcation. NadD and NadRh proteins were puriﬁed using standard
protocolsandrefoldingprocedures(NadRh)asdescribedinTextS1inthe
supplemental material.
Enzyme activity assays and steady-state kinetic analysis. Enzymatic
characterization of puriﬁed proteins was performed using a series of spe-
ciﬁc assays, including continuous and discontinuous coupled enzyme as-
says and direct high-performance LC (HPLC) analysis slightly modiﬁed
from references 5 and 8 and described in Text S1 in the supplemental
material.
Induced degradation of NadD and NadE enzymes in the M. smeg-
matis model. To deplete levels of a targeted protein, we used the Clp
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lized the natural proteolytic process of the M. smegmatis Clp system, spe-
ciﬁcally, ClpP and several accessory proteins, which identify protein tar-
gets and help degrade them. We employed this system to generate
knockdownstrainsofNadDandNadEinM.smegmatis(seeTextS1inthe
supplemental material).
EffectsofNadDandNadEknockdownonviability.Thedetailedpro-
tocolforNadDandNadEknockdowngrowthexperimentsisdescribedin
Text S1 in the supplemental material. Total protein lysates were prepared
andstandardizedbyvaluescorrespondingtotheopticaldensityat600nm
(OD600) and then lysed by bead beating. Western blot analysis was per-
formed as previously described (39). Detection was performed using Su-
perSignal West Femto chemiluminescent substrate (Thermo Scientiﬁc)
according the manufacturer’s protocol.
EffectsofNadDandNadEknockdownonlevelsofNAD-relatedme-
tabolites by LC-MS analysis. Levels of NAD, NaAD, and NaMN in M.
smegmatis were quantiﬁed using a reverse-phase liquid
chromatography—multiple-reaction monitoring–mass spectrometry
(LC-MRM-MS) assay as described in Text S1 in the supplemental mate-
rial.
13C biosynthetic labeling and GC-MS-based metabolic proﬁling.
The labeling experiments were performed with the engineered M. smeg-
matis strains NadD KD and NadE KD. The analyses of polar metabolites
and fatty acids by GC-MS were done as described previously (33). Proto-
cols used for sample collection, derivatization, and GS-MS analysis are
provided in Text S1 in the supplemental material.
Assessing the functional role of NadRh. (i) To study the effect of
M. bovis NadRh expression on the ability to rescue NadD and NadE
knockdown in M. smegmatis model, the corresponding gene was intro-
duced on pUC57:Amp into the respective engineered M. smegmatis
strainsandwasfollowedbyknockdownviabilityexperimentsasdescribed
in Text S1 in the supplemental material. (ii) To assess the functional
importanceofNadRh,thecorrespondinggenewasknockedoutinM.bo-
vis (see Fig. S3 in the supplemental material).
Relative ATP activity levels. Fresh cells from knockdown growth
curvesweremixed1:1withBacTiter-Glo(Promega)reagentperthespec-
iﬁcations of the manufacturer. Luminescence was determined in a 96-
well-format Fluoroskan Ascent FL plate reader (Thermo).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org
/lookup/suppl/doi:10.1128/mBio.00747-13/-/DCSupplemental.
Text S1, DOCX ﬁle, 0.1 MB.
Figure S1, TIF ﬁle, 1.8 MB.
Figure S2, TIF ﬁle, 1.2 MB.
Figure S3, TIF ﬁle, 0.8 MB.
Figure S4, TIF ﬁle, 0.5 MB.
Table S1, DOCX ﬁle, 0 MB.
Table S2, DOCX ﬁle, 0 MB.
Table S3, DOCX ﬁle, 0 MB.
Table S4, DOCX ﬁle, 0 MB.
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